Home  >  News
Diagnostics + Font Resize -

Integrity Applications inks pact with MediReva for distributing non-invasive glucose monitoring device, GlucoTrack in Netherlands

Ashdod, Israel
Saturday, December 30, 2017, 15:00 Hrs  [IST]

Integrity Applications, innovator of GlucoTrack, a non-invasive device for measuring glucose levels in people with type 2 diabetes and pre-diabetes, has entered into an exclusive distribution agreement with MediReva B.V. for the GlucoTrack in the Netherlands.

According to the International Diabetes Federation, as of 2017, there are an estimated number of 970,000 adults living with diabetes in the Netherlands, representing approximately 5.7% of the adult population. The agreement became effective on December 22, 2017.

MediReva, a family owned business for almost 40 years, consists of a group of companies focused on home healthcare and the distribution of specialty medical products with extensive experience with blood glucose monitoring and diabetes care.

Paul Ummels, chief executive officer of MediReva, expressed, "MediReva is one of the leading home care support companies in the Netherlands. We have years of experience in helping patients manage their diabetes and we are excited about bringing GlucoTrack to the marketplace."

MediReva's national coverage spans the entire Netherlands, as well as a strong presence in Belgium and Luxembourg.  In addition, MediReva and its management team have close relationships and a demonstrated track record with local key opinion leaders, insurance companies and other reimbursement authorities.

As part of the agreement, MediReva has committed substantial resources, including the hiring of dedicated sales and customer support staff, exclusively for the distribution of GlucoTrack.

David Podwalski, Integrity's chief commercial officer, commented, "This distribution agreement in the Netherlands is a major milestone on our path to commercializing GlucoTrack. It represents an important first program in our updated commercial partnering strategy. We are excited to work with MediReva to launch GlucoTrack in the Netherlands, and we look forward to continuing our efforts in making the device available for patients in markets around the world."

Commercialization of GlucoTrack in Europe is one of Integrity's near-term priorities.  An overhaul of the previous commercial strategy has been implemented, including changes to product pricing and positioning, distribution channels and geographic focus.  The Netherlands represents an important first market for creation of a scalable blueprint to be used in other European markets where there are approximately 58 million people living with diabetes, representing approximately 8.8% of the adult population.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
CPhI-WW-Banners-150X60-120618-anim-v2
pharmalytica_150x60_2018
CPhI_MEA_Banner_150x60_2018
150X60px_biowavers
IPE_2018_Banner_150X60
GPRS_150x60_2018
cphikorea_150x60_saffron media
Chemspec_India-2018
CPhI_China_150x60-2018
PharmaTech_Expo_2018
VF118_Banner_150x60_E_D2
IPJPI18_150x60en_2018
 
 
 
 
Copyright © 2016 Saffron Media Pvt. Ltd |